Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy
- 9 December 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 16 (4), 572-582
- https://doi.org/10.1016/j.jtho.2020.11.017
Abstract
No abstract availableKeywords
Funding Information
- Janssen Pharmaceuticals
- Bristol-Myers Squibb
This publication has 29 references indexed in Scilit:
- The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the InevitableLung Cancer, 2016
- ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncologyAnnals of Oncology, 2016
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping AlterationsJournal of Thoracic Oncology, 2016
- MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor PrognosisClinical Cancer Research, 2016
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met OverexpressionJournal of Clinical Oncology, 2016
- Clinicopathological Characteristics of RET Rearranged Lung Cancer in European PatientsJournal of Thoracic Oncology, 2016
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET InhibitorsCancer Discovery, 2015
- ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variabilityOncotarget, 2015
- MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the LungClinical Cancer Research, 2015
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancerNature Genetics, 2012